December 07, 2017
A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.
December 05, 2016
Aegerion Pharmaceuticals Inc. on Monday said it has agreed to pay $22.25 million to settle an investor class action in Massachusetts federal court alleging the biopharmaceutical company misled shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.
January 16, 2014
Aegerion Pharmaceuticals Inc. was hit with a proposed class action in Massachusetts federal court Wednesday accusing the biopharmaceutical company of misleading shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.